Penumbra, Inc. (PEN) is a Medical - Devices company in the Healthcare sector, currently trading at $332.17. It has a SharesGrow Score of 67/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of PEN = $304.88 (-8.2% from the current price, the stock appears fairly valued). Analyst consensus target is PEN = $372 (+12% upside).
Valuation: PEN trades at a trailing Price-to-Earnings (P/E) of 72.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.76.
Financials: revenue is $1.4B, +18.4%/yr average growth. Net income is $178M, growing at +1908.9%/yr. Net profit margin is 12.7% (healthy). Gross margin is 67.1% (+3.9 pp trend).
Balance sheet: total debt is $220M against $1.4B equity (Debt-to-Equity (D/E) ratio 0.15, conservative). Current ratio is 6.64 (strong liquidity). Debt-to-assets is 12%. Total assets: $1.8B.
Analyst outlook: 9 / 22 analysts rate PEN as buy (41%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 32/100 (Fail), Growth 90/100 (Pass), Past 75/100 (Partial), Health 100/100 (Pass), Moat 80/100 (Pass), Future 40/100 (Partial), Income 55/100 (Partial).
